Navigation Links
News briefs from the February issue of Chest
Date:2/4/2010

BENEFITS OF ICS FOR COPD MAY BE OVERSTATED

Inhaled corticosteroids (ICS) are widely used for the treatment of chronic obstructive pulmonary disease (COPD). However, new research suggests that ICS may only provide a modest benefit in reducing exacerbations in patients with COPD. Researchers from India conducted a metaanalysis of 11 studies (8,164 patients) that reported the efficacy of ICS versus placebo in prevention of COPD exacerbations. The use of ICS was associated with a modest reduction in the occurrence of exacerbations, with a subgroup analysis revealing only a benefit in patients with a FEV1 less than 50 percent. Upon further analysis using metaregression, the researchers found no demonstrable linear relationship between the efficacy of ICS and prevention of COPD exacerbation that was related to the level of stable lung function. Researchers conclude that the role of ICS in preventing COPD exacerbations warrants reexamination. This article is published in the February issue of Chest, the peer-reviewed journal of the American College of Chest Physicians: Chest 2010; 137(2):318-325.

MAJORITY OF TB PATIENTS DO NOT COMPLETE THERAPY

New research shows that less than half of patients starting treatment for latent TB infection (LTBI) actually complete therapy. Researchers from several major medical institutions, including Boston University School of Public Health, found that at 32 clinics in the United States and Canada, 123 of 720 patients tested and offered treatment for LTBI declined. Furthermore, of 1,994 patients who started treatment for LTBI in 68 US and Canadian clinics, 1,045 failed to complete therapy. Employees at health-care facilities were most likely to decline treatment altogether, while those in congregate settings, such as nursing homes and jail, were least likely to complete therapy. The article is published in the February issue of Chest, the peer-reviewed journal of the American College of Chest Physicians: Chest 2010; 137(2):401-409.

PATIENTS WITH COPD HAVE INCREASED RISK FOR DEPRESSION

A new study provides further evidence that patients with chronic obstructive pulmonary disease (COPD) are at an increased risk for developing depression. Researchers from Switzerland compared the prevalence of depression among 35,722 patients with COPD with 35,722 patients who were COPD-free. Results showed that the prevalence of diagnosed depression prior to the first COPD diagnosis was higher in the COPD population (23.1 percent) than among patients without COPD (16.8 percent). In addition, the incidence rate of a new-onset diagnosis of depression after the first COPD diagnosis was 16.2/1,000 person-years in the COPD group, compared with 9.4/1,000 person-years in the group without COPD. Patients with severe COPD had the highest risk of developing depression. This study is published in the February issue of Chest, the peer-reviewed journal of the American College of Chest Physicians: Chest 2010; 137(2):341-347.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. News briefs from the January issue of Chest
2. Plastic Surgery 2009 news briefs
3. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 27
4. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 26
5. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25
6. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24
7. News briefs from the October issue of Chest
8. News briefs from the August issue of Chest
9. Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs)
10. News briefs from the July issue of CHEST
11. News briefs from the June issue of CHEST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: